{"schema_version":"secwatch.filing_event.v1","accession":"0001829126-23-002648","form_type":"8-K","ticker":null,"cik":"0000910267","company_name":"TITAN PHARMACEUTICALS INC","filed_at":"2023-04-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:42.754739+00:00","generated_at":"2026-06-17T03:58:01.594212+00:00","sec_items":["3.01","5.08","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Titan Pharma receives Nasdaq deficiency notice for stockholders' equity below $2.5M","bullets":["Stockholders' equity of $1.363M as of Dec 31, 2022, below Nasdaq's $2.5M minimum.","Company has 45 days to submit a compliance plan; may get up to 180 days to cure.","2022 annual meeting set for June 19, 2023; record date May 1, 2023.","Shareholder proposals due by April 24, 2023 for inclusion in proxy materials.","Listing on Nasdaq Capital Market unaffected for now while company evaluates options."],"urls":{"canonical":"https://secwatch.observer/filing/0001829126-23-002648","json":"https://secwatch.observer/filing/0001829126-23-002648.json","markdown":"https://secwatch.observer/filing/0001829126-23-002648.md","text":"https://secwatch.observer/filing/0001829126-23-002648.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/0001829126-23-002648-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/titanpharma_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T03:58:01.594212+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"358678cd139747a90cf4e4ddc47b04ed21a7c0ea","claim":"TITAN PHARMACEUTICALS INC received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).","evidence_excerpt":"for the Nasdaq Capital Market, which requires that a listed company’s stockholders’ equity be at least $2,500,000. In its 2022 10-K, the Company reported stockholders’ equity of $1,363,000, and, as a result, does not currently satisfy Nasdaq Marketplace Rule 5550(b)(1). The Notice has no immediate effect on the Company’s listing on the Nasdaq Capital Market. In","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/910267/000182912623002648/0001829126-23-002648-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"deficiency notice"},{"label":"Deficiency","value":"stockholders equity"},{"label":"Rules","value":"5550(b)(1)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}